+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2020 Europe Molecular Diagnostic Analyzers and Reagent Forecasts for 100 Tests: France, Germany, Italy, Spain, UK - Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing - Supplier Shares, Emerging technologies, Instrumentation Review, Opportunities

  • PDF Icon

    Report

  • 1273 Pages
  • March 2020
  • Region: Europe, France, Germany, Italy, Spain, United Kingdom
  • VPG Market Research
  • ID: 4846531
This new 1,273-page comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.

Contains 1,273 pages and 139 tables

Companies Mentioned

Competitive Assessments

- Abbott

  • Affymetrix
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biokit
  • bioMerieux
  • Bio-Rad
  • Biotest
  • Cepheid
  • Decode Genetics
  • Diadexus
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Exact Sciences
  • Fujirebio
  • Grifols
  • Hologic
  • Illumina
  • LabCorp
  • Leica Biosystems
  • Li-Cor Biosciences
  • Myriad Genetics
  • Ortho-Clinical Diagnostics
  • PerkinElmer
  • Proteome Sciences
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • Shimadzu
  • Siemens Healthineers
  • Sierra Molecular
  • Takara Bio
  • Tecan Group
  • Thermo Fisher